X

Drug Profile

Research programme: CD8 Treg modulators - Mozart Therapeutics

Alternative Names: Research programme: CD8 T regulatory cell modulators - Mozart Therapeutics

Latest Information Update: 16 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mozart Therapeutics
Class Anti-inflammatories
Mechanism of Action CD8 positive T lymphocyte modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

10 May 2022 Preclinical trials in Autoimmune disorders in USA (unspecified route), prior to May 2022
10 May 2022 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route), prior to May 2022
26 Oct 2021 Mozart Therapeutics in-license technology related to T cell biology from Stanford University School of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com